Note 9 - Business Segment Information (Tables)

9 Months Ended

Sep. 30, 2022

Notes Tables

Schedule of Segment Reporting Information, by Segment [Table Text Block]

	Three months ended September 30,						Nine months ended September 30,
	2022			2021			2022			2021
Revenue
BioLargo corporate	$	2		$	—		$	4		$	7
ONM		1,199			420			2,499			1,058
BLEST		401			416			1,613			1,070
Water		1			2			1			9
Clyra Medical		17			9			34			114
Intersegment revenue		(120	)		(135	)		(365	)		(522	)
Total	$	1,500		$	712		$	3,786		$	1,743
Operating income (loss)
BioLargo corporate	$	(783	)	$	(868	)	$	(2,925	)	$	(2,726	)
ONM		400			(72	)		418			(355	)
Clyra Medical		(240	)		(219	)		(736	)		(958	)
BLEST		(179	)		(140	)		(158	)		(513	)
Water		(141	)		(156	)		(572	)		(461	)
Total	$	(943	)	$	(1,455	)	$	(3,973	)	$	(5,013	)
Interest expense
BioLargo corporate	$	(6	)	$	(6	)	$	(18	)	$	(106	)
Clyra Medical		(8	)		(20	)		(24	)		(96	)
Total	$	(14	)	$	(26	)	$	(42	)	$	(208	)
Research and development expense
BioLargo corporate	$	(140	)	$	(220	)	$	(570	)	$	(765	)
Clyra Medical		(31	)		(20	)		(73	)		(53	)
BLEST		(100	)		(123	)		(288	)		(358	)
Water		(119	)		(109	)		(446	)		(366	)
Intersegment R&D		119			135			359			515
Total	$	(271	)	$	(344	)	$	(1,018	)	$	(1,027	)

As September 30, 2022	BioLargo		ONM		Clyra		BLEST		Water		Elimination			Total
Tangible assets	$	785	$	1,079	$	814	$	590	$	194	$	(20	)	$	3,442
Right of use		157		—		—		739		—		—			896
Investment in South Korean joint venture		33		—		—		—		—		—			33
Total		975		1,079		814		1,329		194		(20	)		4,371

As of December 31, 2021	BioLargo		ONM		Clyra		BLEST		Water		Elimination			Total
Tangible assets	$	690	$	451	$	832	$	445	$	152	$	(47	)	$	2,522
Right of use		222		—		—		231		—		—			453
Investment in South Korean joint venture		48		—		—		—		—		—			48
Total		960		451		832		676		152		(47	)		3,023